When prostate cancer spreads to the spine, it raises an important question: is Lu-177 PSMA therapy still safe? Bone metastases in the spine (cancer in the bones of the spine) are common in advanced prostate cancer. Many men wonder if being treated near the spinal cord makes this therapy riskier. The answer is yes, you can get this therapy, and knowing why will help you talk with your oncology team.
What "Spinal Bone Metastases" Actually Means
The spine is one of the most common places where prostate cancer spreads. But "spine metastases" is not one thing. Different parts of the spine can be involved, and each matters differently when thinking about Lu-177 PSMA therapy.
- Vertebral bone lesions: Cancer inside the bony structure of a vertebra. This is the most common type of spinal involvement in prostate cancer, and many men with this pattern do receive Lu-177 PSMA therapy.
- Epidural disease: Cancer that has grown outside the bone and is pressing toward, but not directly on, the spinal cord or nerve roots.
- Active spinal cord compression: Cancer that is directly pressing on the spinal cord or causing new neurological symptoms like weakness, numbness, or changes in bladder or bowel function. This situation raises the most urgent safety concerns.
Most men with spinal bone metastases have cancer inside the vertebral bone, not actively pressing on the cord. Your care team will check which type you have before recommending Lu-177 PSMA therapy.
How Lu-177 PSMA Works and Why the Spinal Cord Is Not Its Target
Lu-177 PSMA therapy works by delivering a radioactive particle directly to prostate cancer cells. It does this by attaching to a protein called PSMA (prostate-specific membrane antigen), which sits on the surface of most prostate cancer cells. The therapy travels through the bloodstream and binds to PSMA-positive cancer cells, including those inside vertebrae.
This is different from external beam radiation. External radiation passes through tissue from outside the body, hitting whatever is in its path. Lu-177 PSMA targets cancer cells specifically. It does not deliberately target spinal cord tissue unless that tissue contains PSMA-expressing prostate cancer cells.
There are indirect effects to understand. When the therapy reaches cancer cells inside bones, some radiation reaches nearby tissue, including bone marrow, which produces blood cells. This "bystander effect" is the main safety concern in patients with extensive spinal and bone metastases, not direct cord damage.
For more on what Lu-177 PSMA may do for patients with bone involvement, see our article on whether Lu-177 PSMA may help with bone pain from metastases.
What the Clinical Evidence Says About Safety
The VISION trial is the largest study of Lu-177 PSMA-617 to date. It enrolled 831 men with metastatic castration-resistant prostate cancer (mCRPC) who had previously received hormone therapies and at least one round of chemotherapy. The trial found that Lu-177 PSMA-617 improved overall survival and slowed cancer growth compared to standard care alone. These results, published on PubMed Central via the National Institutes of Health, also documented the therapy's safety profile across a broad patient population, including many with bone metastases.
The most common serious side effects in the VISION trial were fatigue, nausea, dry mouth, and lower blood cell counts. Spinal bone lesions alone did not make the therapy unsafe. However, the study excluded patients with active, symptomatic spinal cord compression.
A detailed review of blood cell safety, published on PubMed Central, found that serious blood count drops occurred in about 9.3% of treated patients (roughly 1 in 11). This risk was higher in patients who already had low blood counts before starting treatment and in those with many bone metastases.
The Main Concern: Bone Marrow and Blood Cell Counts
To understand the safety picture with spinal metastases, you need to know about bone marrow. The marrow inside your bones, including the spine, is where red and white blood cells and platelets are made. When prostate cancer spreads into the spine and other bones, it can crowd out healthy marrow and reduce its ability to make blood cells.
When Lu-177 PSMA reaches cancer cells inside bone, some radiation reaches the surrounding marrow. In men with a few bone lesions, this bystander effect tends to be manageable and reversible. In men with cancer throughout many bones, where cancer has replaced a large portion of the marrow space, this effect is stronger and carries greater risk.
A study of men with extensive bone marrow involvement, available through PubMed Central, found that Lu-177 PSMA therapy could still be used in this group, but required careful monitoring and sometimes dose changes or delayed cycles. Patients with already-low blood counts before treatment had the highest risk of significant blood cell damage. These patients need closer monitoring, not exclusion from treatment.
This is why your doctor will check your bone tumor burden and baseline blood counts before treatment starts. To learn more about protecting your skeleton and blood health during treatment, see our article on bone density and fracture risk during Lu-177 PSMA therapy.
Active Spinal Cord Compression: The Critical Safety Boundary
Lu-177 PSMA therapy excludes patients with active spinal cord compression. If you are currently experiencing new symptoms like leg or arm weakness, loss of bladder or bowel control, or numbness that travels down your back because cancer is pressing on your spinal cord, you are generally not eligible for Lu-177 PSMA at that moment.
The reason goes beyond Lu-177 potentially making compression worse. Active spinal cord compression is a medical emergency. It requires urgent treatment, usually external beam radiation aimed at the affected spine level, or sometimes surgery, to prevent permanent nerve damage. Starting a systemic therapy at that moment would delay the urgent local care your spinal cord needs, and Lu-177 PSMA does not provide the rapid, targeted pressure relief that a compressed cord requires.
A clinical practice review, indexed on PubMed Central, notes that relative contraindications for Lu-177 PSMA therapy include acute bone complications like fractures and spinal cord compression. The word "relative" matters. It means the situation is a barrier at that specific time, not a permanent closed door.
If You Have Had Prior Spinal Treatment, You May Still Qualify
Many patients don't know that past spinal cord compression doesn't automatically disqualify you from Lu-177 PSMA therapy. Multiple clinical trials have allowed patients with a prior history of epidural disease or spinal cord involvement if those areas were treated, are stable on imaging, and the patient has no ongoing symptoms at enrollment.
If your vertebral metastasis was treated with focused external radiation several months ago, is now stable on your most recent scan, and you have no new neurological symptoms, your team can still consider you for Lu-177 PSMA eligibility. Your current status matters more than your history.
This difference between active disease and previously treated, stable disease is a key distinction. If you are unsure whether your history of spinal involvement affects your current eligibility, ask your oncologist or nuclear medicine doctor directly.
What Your Care Team Will Check Before and During Each Cycle
Even in patients who qualify for Lu-177 PSMA therapy with vertebral bone metastases, you'll need regular monitoring throughout every cycle. Treating centers typically check these things:
- Blood counts before every cycle. Your red and white blood cells and platelets need to be at safe levels before each infusion. If counts are too low, your doctor may delay the cycle or lower the dose.
- Assessment of bone tumor burden. PSMA PET/CT imaging helps estimate how much of the skeleton is involved and guides decisions about how much marrow may be at risk from radiation bystander effects.
- Kidney function tests. Lu-177 PSMA is cleared through the kidneys. Your kidneys need to work well, so they're checked regularly.
- Neurological symptom review at every visit. Report any new weakness, bladder or bowel changes, or unusual back pain right away.
- Spine imaging if symptoms change. If new neurological symptoms arise during a treatment course, your team will get a targeted MRI of the spine to check whether a vertebral lesion is pressing on your cord or nerves.
Some specialized centers use dosimetry to estimate radiation to bone marrow and reduce blood cell damage. Ask if your center offers this.
What You Can Do Before Your Appointment
If you have spine metastases and are exploring Lu-177 PSMA therapy, coming prepared helps your doctor help you. Consider gathering the following before you meet with your oncologist or nuclear medicine specialist:
- Copies of recent MRI or CT scans of the spine, along with the radiology reports.
- Your most recent PSMA PET scan results and report, if you have had one.
- A clear summary of any neurological symptoms you have experienced, when they began, whether they improved, and what helped.
- A list of any prior radiation treatment to the spine, including which vertebral levels were treated and approximately when.
- Your most recent complete blood count (CBC) results.
The more complete the picture your team has, the more precisely they can assess your eligibility and plan the monitoring that fits your situation.
For a broader overview of how doctors track and manage side effects throughout the full treatment course, our article on the real-world side effects of Lu-177 PSMA therapy and how they are managed covers the key patterns patients and caregivers should know.
When to Talk to Your Doctor
Talk to your oncologist or nuclear medicine team promptly if you notice any of the following at any time before, during, or between Lu-177 PSMA treatment cycles:
- New weakness or heaviness in the legs or arms that has not been there before.
- Numbness or tingling that travels down your back or into your limbs.
- Any new difficulty controlling bladder or bowel function. This is urgent and needs same-day attention.
- Back pain that feels different from your usual pattern, especially if it wakes you at night or comes with new sensory changes.
- Unusual fatigue, easy bruising, or frequent infections that may signal low blood counts between cycles.
These symptoms may not be serious, but your care team needs to evaluate them without delay. Early reporting helps your team find problems early.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Can I receive Lu-177 PSMA therapy if I have metastases in my spine?
Many men with vertebral bone metastases — cancer inside the bones of the spine — do receive Lu-177 PSMA therapy. The key question is whether you currently have active spinal cord compression causing neurological symptoms. If your lesions are stable, you have no new neurological symptoms, and your blood counts are adequate, your oncologist may still evaluate you as a candidate. Each case is assessed individually based on your bone tumor burden, blood counts, neurological status, and prior treatment history.
Does Lu-177 PSMA radiation reach or damage the spinal cord?
Lu-177 PSMA attaches to PSMA-positive prostate cancer cells, not to spinal cord tissue itself. It does not deliberately target the spinal cord. However, because it delivers radiation to cancer cells inside bones — including vertebrae — nearby bone marrow receives some indirect radiation exposure. In patients with many spinal and skeletal lesions, this can affect blood cell production. The spinal cord tissue itself is not the target, but bone marrow health requires close monitoring throughout treatment.
What is spinal cord compression, and why does it affect eligibility for Lu-177 PSMA?
Spinal cord compression means cancer is physically pressing on the spinal cord, causing symptoms like leg weakness, numbness, or loss of bladder or bowel control. This is a medical emergency requiring urgent treatment — usually focused external radiation — before systemic therapies like Lu-177 PSMA can be considered. Active cord compression is listed as an exclusion criterion in Lu-177 PSMA clinical trials. If it has been treated and is now stable, you may still be evaluated for Lu-177 PSMA therapy at a later point.
What blood tests matter most before starting Lu-177 PSMA if I have many bone metastases?
Your care team will check your complete blood count — specifically hemoglobin (red blood cells), platelet count, and white blood cell count — before every cycle. In patients with extensive bone metastases, these numbers are monitored especially closely because bone marrow, where blood cells are produced, can receive indirect radiation from the therapy. Pre-existing low blood counts are a known risk factor for more serious blood toxicity, so baseline values matter before treatment begins.
If I had prior radiation to my spine, can Lu-177 PSMA still be used?
Prior external radiation to the spine does not automatically disqualify you from Lu-177 PSMA therapy. Clinical trials have included patients with previously treated spinal or epidural disease, provided those areas were stable on imaging and the patient had no new neurological symptoms at the time of treatment. Your oncologist will review your prior radiation history, current imaging, and any neurological symptoms to make an individualized decision about eligibility.